S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Options Trading Plan–Perfect For Beginners (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Options Trading Plan–Perfect For Beginners (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Options Trading Plan–Perfect For Beginners (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
High-speed rail was touted as a game-changer in Britain. Costs are making the government think twice
BREAKING: Tiny biotech successfully treats blindness (Ad)
Stock market today: Asian shares mostly lower after Wall St has its worst week in 6 months
Writers Guild and Hollywood studios reach tentative deal to end strike. No deal yet for actors
Options Trading Plan–Perfect For Beginners (Ad)
AI is on the world's mind. Is the UN the place to figure out what to do about it?
Facial recognition technology jailed a man for days. His lawsuit joins others from Black plaintiffs
New AI Stock Payouts (Ad)
The UN's top tech official discusses AI, bringing the world together and what keeps him up at night
Canadian autoworkers ratify new labor agreement with Ford
NASDAQ:BLCM

Bellicum Pharmaceuticals (BLCM) Stock Forecast, Price & News

$0.48
+0.11 (+29.02%)
(As of 09/22/2023 08:53 PM ET)
Compare
Today's Range
$0.32
$0.48
50-Day Range
$0.28
$0.56
52-Week Range
$0.15
$1.50
Volume
5,400 shs
Average Volume
1.07 million shs
Market Capitalization
$4.56 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BLCM stock logo

About Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock

Bellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.

BLCM Price History

BLCM Stock News Headlines

BLCM - Bellicum Pharmaceuticals, Inc.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Short Volatility Alert: Bellicum Pharma
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Why Bellicum Pharmaceuticals Stock Is Plunging Today
BLCM Bellicum Pharmaceuticals, Inc.
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Company Calendar

Last Earnings
8/10/2023
Today
9/24/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
13
Year Founded
N/A

Profitability

Net Income
$-24,970,000.00
Pretax Margin
-1,922.27%

Debt

Sales & Book Value

Annual Sales
$1.50 million
Book Value
$0.23 per share

Miscellaneous

Free Float
8,518,000
Market Cap
$4.56 million
Optionable
Optionable
Beta
1.40
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. Charles S. Grass (Age 63)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 53)
    Sr. VP of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 65)
    Chief Scientific Officer
    Comp: $536.43k













BLCM Stock - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCM, but not buy additional shares or sell existing shares.
View BLCM analyst ratings
or view top-rated stocks.

How have BLCM shares performed in 2023?

Bellicum Pharmaceuticals' stock was trading at $0.72 on January 1st, 2023. Since then, BLCM shares have decreased by 33.4% and is now trading at $0.4797.
View the best growth stocks for 2023 here
.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our BLCM earnings forecast
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) issued its earnings results on Thursday, August, 10th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals's stock reverse split on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), CyberArk Software (CYBR), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE) and Inovio Pharmaceuticals (INO).

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an IPO on Thursday, December 18th 2014. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

Who are Bellicum Pharmaceuticals' major shareholders?

Bellicum Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Boxer Capital LLC (4.74%).
View institutional ownership trends
.

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $0.48.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $4.56 million and generates $1.50 million in revenue each year.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (281) 454-3424 or via email at robert.uhl@westwicke.com.

This page (NASDAQ:BLCM) was last updated on 9/25/2023 by MarketBeat.com Staff

My Account -